News
MarketBeat on MSN18h
Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher?Nektar Therapeutics (NASDAQ: NKTR) stock exploded nearly 157% following news that Rezpeg, the company’s experimental ...
U.S. Treasury bonds, traditionally seen as one of the world’s safest financial assets, are suffering a sharp sell-off as ...
Among the S&P 500 real estate stocks, Equinix ( EQIX) led the losers. The stock sank 11.07% from the prior week as Raymond ...
J.P. Morgan analyst Daniel Politzer initiated coverage with a Buy rating on DraftKings (DKNG – Research Report) on June 23 and set a price target of $50.00. The company’s shar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback